Zoetis Inc. $ZTS Shares Bought by Cwm LLC

Cwm LLC raised its holdings in Zoetis Inc. (NYSE:ZTS) by 60.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 35,922 shares of the company’s stock after purchasing an additional 13,555 shares during the period. Cwm LLC’s holdings in Zoetis were worth $5,602,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Nova Wealth Management Inc. acquired a new position in shares of Zoetis in the 1st quarter valued at approximately $25,000. 1248 Management LLC acquired a new position in shares of Zoetis in the 1st quarter valued at approximately $27,000. Saudi Central Bank acquired a new position in shares of Zoetis in the 1st quarter valued at approximately $29,000. Cornerstone Planning Group LLC raised its position in shares of Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after purchasing an additional 88 shares in the last quarter. Finally, REAP Financial Group LLC raised its position in shares of Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after purchasing an additional 131 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ZTS. Stifel Nicolaus lowered Zoetis from a “buy” rating to a “hold” rating and cut their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Finally, Piper Sandler boosted their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Four investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Hold” and an average target price of $196.71.

Zoetis Price Performance

Shares of ZTS opened at $142.08 on Thursday. The company has a market cap of $62.97 billion, a P/E ratio of 24.45, a PEG ratio of 2.30 and a beta of 0.90. The stock has a fifty day moving average price of $148.89 and a 200 day moving average price of $154.03. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $196.55.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm’s revenue was up 4.2% on a year-over-year basis. During the same period in the prior year, the business earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio is presently 34.42%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.